**We claim:**

1. A pharmaceutical composition comprising:

(a) an anti-nerve growth factor (NGF) antibody, or antigen binding fragment thereof;

(b) a histidine buffer at a concentration of about 5 to about 60 mM; and

(c) polysorbate 80 at a concentration of about 0.01% to about 0.1%;

wherein the pH of the composition is about 5.0 to about 6.0.

2. The pharmaceutical composition of claim 1, wherein said composition comprises about 10 to about 30 mM histidine.

3. The pharmaceutical composition of claim 1, wherein the pH is about 5.5.

4. The pharmaceutical composition of claim 1, wherein the composition comprises about 0.01 % to about 0.02% polysorbate 80.

5. The pharmaceutical composition of claim 1, wherein the composition further comprises about 1 to about 100 mg/mL of a polyol.

6. The pharmaceutical composition of claim 5, wherein the polyol is selected from the group consisting of sorbitol and mannitol.

7. The pharmaceutical composition of claim 6, wherein the polyol is mannitol.

8. The pharmaceutical composition of claim 7, wherein the composition comprises about 10 to about 30 mg/mL mannitol.

9. The pharmaceutical composition of claim 1, wherein the composition further comprises about 10 to about 100 mg/mL of a sugar.

10. The pharmaceutical composition of claim 9, wherein the sugar is sucrose.

11. The pharmaceutical composition of claim 10, wherein the composition comprises about 10 to about 70 mg/mL sucrose.

12. The pharmaceutical composition of claim 1, wherein said composition does not comprise a polyol or a sugar.

13. The pharmaceutical composition of claim 1, wherein said composition does not comprise methionine.

14. The pharmaceutical composition of claim 1, wherein the concentration of the antibody, or antigen-binding portion thereof, is about 1 to about 240 mg/mL.

15. The pharmaceutical composition of claim 1, wherein the concentration of the antibody, or antigen-binding portion thereof, is about 20 to about 120 mg/mL.

16. The pharmaceutical composition of any one of claims 1-11 and 13-15, wherein the molar ratio of (a) anti-NGF antibody, or antigen binding fragment thereof, to (b) polyol, sugar, or combination thereof, is greater than 1:1400.

17. The pharmaceutical composition of claim 1, wherein said composition comprises:

(a) about 20 mg/mL of the antibody, or antigen-binding portion thereof;

(b) about 15 mM histidine; and

(c) about 0.01% polysorbate 80;

wherein the pH of the formulation is about 5.5.

18. The pharmaceutical composition of claim 1, wherein said composition comprises:

(a) about 60 mg/mL of the antibody, or antigen-binding portion thereof;

(b) about 30 mM histidine; and

(c) about 0.02% polysorbate 80;

wherein the pH of the formulation is about 5.5.

19. The pharmaceutical composition of claim 1, which is suitable for lyophilization.

20. A lyophilized pharmaceutical composition comprising:

(a) about 1 to about 120 mg of an anti-NGF antibody, or antigen binding fragment thereof;

(b) about 1 to about 10 mg of histidine; and

(c) about 0.1 to about 0.4 mg of polysorbate 80.

21. The lyophilized pharmaceutical composition of claim 20, wherein the composition comprises:

(a) about 60 mg of an anti-NGF antibody, or antigen binding fragment thereof;

(b) about 4.7 mg of histidine; and

(c) about 0.2 mg of polysorbate 80.

22. The lyophilized pharmaceutical composition of claim 20, wherein the composition comprises:

(a) about 20 mg of an anti-NGF antibody, or antigen binding fragment thereof;
(b) about 2.3 mg of histidine; and
(c) about 0.1 mg of polysorbate 80.

23. The lyophilized pharmaceutical composition of any one of claims 20 to 22, further comprising about 1 to about 100 mg of a polyol.

24. The lyophilized pharmaceutical composition of claim 23, wherein the polyol is about 10 to about 50 mg mannitol.

25. The lyophilized pharmaceutical composition of any one of claims 20 to 24, further comprising about 1 to about 100 mg of a sugar.

26. The lyophilized pharmaceutical composition of claim 25, wherein the sugar is about 1 to 100 mg sucrose.

27. The pharmaceutical composition of any one of the preceding claims, wherein the anti-NGF antibody, or antigen-binding portion thereof, binds to human NGF.

28. The pharmaceutical composition of any one of the preceding claims, wherein the anti-NGF antibody, or antigen-binding portion thereof, comprises a human IgG4 constant region.

29. The pharmaceutical composition of any one of the preceding claims, wherein the anti-NGF antibody, or antigen-binding portion comprises a hinge region mutation.

30. The pharmaceutical composition of claim 29, wherein the hinge region mutation comprises a mutation of a serine at amino acid position 108 of SEQ ID NO: 9.

31. The pharmaceutical composition of claim 29, wherein the serine at amino acid position 108 of SEQ ID NO: 9 is mutated to proline.

32. The pharmaceutical composition of claim 29, wherein the human IgG4 constant region comprises the amino acid sequence of SEQ ID NO: 10.

33. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, has one or more of the following functional properties:

a) binds to human NGF but does not bind to human brain-derived neurotrophic factor (BDNF), human neurotrophin 3 (NT-3) or human neurotrophin 4 (NT-4);

b) binds to human or rat NGF with a $K_D$ of 100 pM or less;
c) inhibits binding of NGF to TrkA or $p75^{NTR}$;
d) inhibits NGF-dependent proliferation of TF-1 cells;
e) inhibits NGF-dependent chick dorsal root ganglion survival; and
f) inhibits NGF-dependent PC12 cell neurite outgrowth.

34. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, does not exhibit a rebound effect when administered to a subject.

35. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising CDRs 1, 2 and 3, having the amino acid sequences of SEQ ID NOs: 3, 4 and 5, respectively.

36. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region comprising CDRs 1, 2 and 3, having the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively.

37. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1.

38. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.

39. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, competes for binding to NGF with an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.

40. The pharmaceutical composition of any one of claims 1-26, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 13.

~~41. The pharmaceutical composition of any one claims 1-26 and 40, wherein the antibody, or antigen binding portion thereof, comprises a light chain comprising the amino acid sequence of SEQ ID NO: 16.~~

1~~42~~. A pharmaceutical composition comprising:

(a) an anti-nerve growth factor (NGF) antibody, or antigen binding fragment thereof, comprising (i) a heavy chain variable region comprising CDRs 1, 2 and 3 having the amino acid sequences of SEQ ID NOs: 3, 4 and 5, respectively, (ii) a light chain variable region comprising CDRs 1, 2 and 3 having the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively, and (iii) a human IgG4 constant region having the amino acid sequence of SEQ ID NO:10, wherein the concentration of the antibody, or antigen binding fragment thereof, is ~~about~~ 10 to ~~about~~ 50 mg/mL;

(b) a histidine buffer at a concentration of ~~about~~ 10 to ~~about~~ 30 mM histidine; and

(c) polysorbate 80 at a concentration of ~~about~~ 0.01% to 0.02%;

wherein the pH of the composition is ~~about~~ 5.0 to ~~about~~ 6.0.

~~43. A pharmaceutical composition comprising:~~

~~(a) an anti-nerve growth factor (NGF) antibody comprising (i) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1, (ii) a light chain variable region having the amino acid sequence of SEQ ID NO:2, and (iii) a human IgG4 constant region comprising a hinge region mutation at position 108 of SEQ ID NO: 9, wherein the concentration of the antibody, or antigen binding fragment thereof, is about 10 to about 50 mg/mL;~~

~~(b) a histidine buffer at a concentration of about 10 to about 30 mM histidine; and~~

~~(c) polysorbate 80 at a concentration of about 0.01% to 0.02%;~~

~~wherein the pH of the composition is about 5.0 to about 6.0.~~

2~~44~~. The ~~A~~ pharmaceutical composition of claim 1, wherein said ~~comprising:~~

~~(a)~~ an anti-nerve growth factor (NGF) antibody ~~comprising a human IgG4 constant region, wherein the antibody~~ comprises a heavy chain having the amino acid sequence of SEQ ID NO:13 and a light chain having the amino acid sequence of SEQ ID NO:16~~, wherein the concentration of the antibody, or antigen binding fragment thereof, is about 10 to about 50 mg/mL;~~

~~(b) a histidine buffer at a concentration of about 10 to about 30 mM histidine; and~~

~~(c) polysorbate 80 at a concentration of about 0.01% to 0.02%;~~

~~wherein the pH of the composition is about 5.0 to about 6.0.~~

345. The pharmaceutical composition of ~~any one of~~ claim~~s~~ 1 or claim 2~~42 to 44~~, further comprising ~~about~~ 10 to ~~about~~ 50 mg/mL mannitol.

446. The pharmaceutical composition of any one of claims 1 to 3~~42 to 45~~, further comprising ~~about~~ 5 to ~~about~~ 70 mg/mL sucrose.

547. The pharmaceutical composition of any ~~one of~~ claim~~s~~ 1 or claim 2, comprising:~~42 to 44, consisting essentially of:~~

(a) ~~about~~ 10 to 30 mg/mL of the antibody or antigen-binding fragment thereof;
(b) ~~about~~ 15 mM histidine buffer; and
(c) ~~about~~ 0.01% polysorbate 80;

wherein the pH of the composition is about 5.5.

648. The pharmaceutical composition of claim 3, comprising:~~45, consisting essentially of:~~

(a) ~~about~~ 10 to 30 mg/mL of the antibody or antigen-binding fragment thereof;
(b) ~~about~~ 15 mM histidine buffer;
(c) ~~about~~ 0.01% polysorbate 80; and
(d) ~~about~~ 10 to 30 mg/mL mannitol;

wherein the pH of the composition is about 5.5.

749. The pharmaceutical composition of claim ~~46~~, comprising:~~consisting essentially of:~~

(a) ~~about~~ 10 to 30 mg/mL of the antibody or antigen-binding fragment thereof;
(b) ~~about~~ 15 mM histidine buffer;
(c) ~~about~~ 0.01% polysorbate 80; and
(d) ~~about~~ 40 to 70 mg/mL sucrose;

wherein the pH of the composition is about 5.5.

8~~50~~. The pharmaceutical composition of claim 5, comprising:~~46, consisting essentially of:~~

(a) ~~about~~ 10 to 30 mg/mL of the antibody or antigen-binding fragment thereof;
(b) ~~about~~ 15 mM histidine buffer;
(c) ~~about~~ 0.01% polysorbate 80;
(d) ~~about~~ 10 to 30 mg/mL mannitol; and
(e) ~~about~~ \5 to 10 mg/mL sucrose;

wherein the pH of the composition is about 5.5.

9~~51~~. The pharmaceutical composition of any one of claims 3 to 8~~42 to 50~~, wherein the ratio of antibody, or antigen binding fragment thereof, to mannitol ~~polyol~~ and /or sucrose ~~sugar~~ is greater than 1:1400.

10. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, is selected from the group consisting of a monoclonal antibody, a human antibody, a humanized antibody, a chimerical antibody, a CDR-grafted antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody, a diabody, a multispecific antibody, a dual specific antibody, and a bispecific antibody.

1152. The pharmaceutical composition of any one of the preceding claims, ~~42 to 51,~~ wherein the pharmaceutical composition is lyophilized.

~~53. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, is selected from the group consisting of a monoclonal antibody, a human antibody, a humanized antibody, a chimerical antibody, a CDR-grafted antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody, a diabody, a multispecific antibody, a dual specific antibody, and a bispecific antibody.~~

~~54. The pharmaceutical composition of any one of the preceding claims, wherein the antibody, or antigen-binding portion thereof, is the antibody PG110.~~

1255. The pharmaceutical composition of any one of ~~the preceding~~ claims 1 to 11, wherein the formulation is stable ~~in a liquid~~ form for at least about 3 months in a liquid, frozen or lyophilized form such as wherein the formulation is stable for at least 3 months when stored in liquid form at 2-8°C, wherein the formulation is stable for at least 3 months when stored at -80°C, or wherein the formulation is stable for at least 3 months when stored in lyophilized form at 2-8°C, or when stored in lyophilized form at room temperature.

~~56. The pharmaceutical composition of any one of the preceding claims, wherein the formulation is stable in a liquid form for at least about 12 months.~~

~~57. The pharmaceutical composition of any one of the preceding claims, wherein the formulation is stable for at least 3 months in a frozen or lyophilized form.~~

~~58. The pharmaceutical composition of claim 57, wherein the formulation is stable for at least 6 months in frozen or lyophilized form.~~

~~59. The pharmaceutical composition of claim 57, wherein the formulation is stable for at least 12 months in a frozen or lyophilized form.~~

~~59. The pharmaceutical composition of claims 55 or 56, wherein the formulation is stored at 2-8°C.~~

~~60. The pharmaceutical composition of claims 57 or 58, wherein the formulation is stored frozen at -80°C.~~

~~61. The pharmaceutical composition of claims 57 or 58, wherein the formulation is stored in lyophilized form at 2-8°C.~~

~~62. The pharmaceutical composition of claims 57 or 58, wherein the formulation is stored in lyophilized form at room temperature.~~

1363. The pharmaceutical composition of ~~any one of~~ claims ~~1255 to 63~~, wherein there is less than ~~about~~ 10% aggregation of the antibody, such as less than 3% aggregation of the antibody.

~~64. The pharmaceutical composition of any one of claims 55 to 63, wherein there is less than about 3% aggregation of the antibody.~~

1465. The pharmaceutical composition of any one of the preceding claims, wherein the formulation is suitable for intravenous, subcutaneous and/or intramuscular administration.

1566. A device comprising the pharmaceutical composition of any one of the preceding claims, ~~1 65~~ such as a device selected from the group consisting of a syringe, a pen, an implant, a needle-free injection device, an inhalation device, and a patch.

~~67. The device of claim 66, wherein the device is selected from the group consisting of a syringe, a pen, an implant, a needle-free injection device, an inhalation device, and a patch.~~

~~68. An article of manufacture comprising the pharmaceutical composition or device of any one of claims 1-67.~~

~~69. Use of the pharmaceutical composition of any one of claims 1-65, or the device of any one of claims 66-67, to treat an NGF mediated disease or condition.~~

~~70. The use of claim 69, wherein the NGF-mediated disease or condition is pain.~~

~~71. The use of claim 70, wherein the pain is selected from the group consisting of osteoarthritis pain, chronic low back pain, diabetic neuropathic pain, cancer pain, pain from bone metastases, interstitial cystitis, painful bladder syndrome, pain associated with chronic abacterial prostatitis, pain associated with endometriosis, pain associated with uterine fibroids and post-operative pain.~~

~~72. The use of any one of claims 69-71, wherein pharmaceutical compositions is suitable for administration of the anti-NGF antibody, or antigen binding fragment thereof at a dose in a range from 0.1 mg/kg to 10/mg/kg.~~

~~73. The use of any one of claims 69-72, wherein the pharmaceutical composition is suitable for administration intravenously, subcutaneously or intra-articularly.~~

~~74. The use of any one of claims 69-74, wherein the pharmaceutical composition is suitable for administration with a second pharmaceutical agent.~~

~~75. The use of claim 74, wherein the second pharmaceutical agent is selected from the group consisting of NSAIDs, analgesics including opioid analgesics and atypical analgesics, local anaesthetics, nerve blocks, phenol blocks, therapeutic antibodies, steroids, anti-convulsants, anti-depressants, topical capsaicin, antiviral agents, TrkA inhibitors and PKC inhibitors.~~